Selventa Announces a Joint Technology Collaboration with Pfizer Inc., to Include Developing Knowledge-sharing Portal of Bi Read more: Selventa Announces a Joint Technology Collaboration with Pfizer Inc., to Include Developing Knowledge-sharing Portal of
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Selventa™ today announced a continuation and expansion of its strategic partnership with the world’s largest pharmaceutical company, Pfizer Inc., in the areas of biological knowledge dissemination and drug safety. The scope of the new collaboration, co-funded by Pfizer, includes creating a publicly available version of Selventa’s Biological Expression Language (BEL) and associated BEL Framework that will enable organizations to capture, store, combine and use scientific knowledge across a wide range of scientific applications to help inform and streamline decision-making regarding drug targets. The collaboration includes establishing a community of BEL stakeholders and users, and the development of a BEL community portal to disseminate the technology to the scientific community at large.
“The structure of this joint effort enables Selventa to expand its existing technology to develop a knowledge-sharing portal that has the potential to benefit not only Pfizer scientists but also the entire scientific community,” said David de Graaf, President and CEO of Selventa. “We are extremely excited to take our collaboration to the next level and look forward with great anticipation at the prospect of opening our technology platform and working even more closely with cross-functional R&D teams at Pfizer.”
Until recently, Selventa had only used the Genstruct® Technology Platform (GTP) as an internal platform for collaborative research projects with Pfizer and other pharmaceutical partners. Through recent rebranding efforts and collaborations such as this, Selventa is currently transitioning its technology platform and business model to a more open, standards-based approach, thereby enabling broad adoption and use of Selventa tools, infrastructure and knowledge among its customers, their business partners, and the wider scientific community.
“Pfizer is pleased to be part of this collaboration,” said Denise Robinson-Gravatt, Head of Pfizer’s Drug Safety Technology. “The success of our industry to a large extent is determined by new drug innovation, so the more we can make broadly available to the scientific community open-source solutions involving non-proprietary research and technology tools, the more we’re facilitating innovation to occur, which ultimately is a win-win for all stakeholders involved – the scientific community, the pharmaceutical industry and patients.”
Founded in 2002 and privately-held, Selventa helps clients find optimal treatments for the right patients by offering scientific consulting services, software and strategic partnerships. The company analyzes molecular patient data, accelerates the development process and clarifies therapeutics and diagnostics decisions. Selventa engages in short-, mid- and long-term relationships with top-tier pharmaceutical and life science companies to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases, inflammation and drug safety.
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.